Biosimilars (2009 - 2014)----aarkstore Enterprise

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing

demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others.

The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilarss market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Asias early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddys Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

Scope of the Report

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

Biosimilars product market

Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

For more information please contact :

http://www.aarkstore.com/reports/Biosimilars-2009-2014--29843.html

http://blogs.aarkstore.com/

From: Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore

POST COMMENT

Silicon Photonics (2009 - 2014)----aarkstore Enterprise Capgemini-aarkstore Enterprise Middle East Telco Kpis 2009-aarkstore Enterprise The Regulatory Approach To Next-generation Access: Asia-pacific-aarkstore Enterprise Teliasonera International Carrier-aarkstore Enterprise Forecast Update: Rf Optical Components For Cable Tv-aarkstore Enterprise Report On Global Lfp (lifepo4) Industry, 2009----aarkstore Enterprise Installed Capacity Of Wind Power Units In China, 2008 ----aarkstore Enterprise Report On China's Lfp (lifepo4) Industry, 2009----aarkstore Enterprise 2008 Report On China's Rfid Industry ----aarkstore Enterprise Fujitsu Vendor Profile-aarkstore Enterprise Telecom 2020: Transformation Strategies----aarkstore Enterprise Stem Cell Therapies: Advanced-stage Clinical Trials-aarkstore Enterprise